
May 7 (Reuters) - Teva Pharmaceutical Industries Ltd TEVA.TA:
TEVA REPORTS NINTH CONSECUTIVE QUARTER OF GROWTH IN Q1 2025 WITH KEY INNOVATIVE MEDICINES GROWING ~40%; 2025 PROFIT OUTLOOK IMPROVED
TEVA: ON TRACK FOR 30% OPERATING PROFIT MARGIN BY 2027 IN LINE WITH OUR PIVOT TO GROWTH STRATEGY
TEVA: CURRENT, CONFIRMED U.S. TARIFFS EXPECTED TO HAVE IMMATERIAL IMPACT; ABSORBED IN UPDATED 2025 NON-GAAP OUTLOOK
TEVA: ANNOUNCED ABOUT $700 MILLION NET SAVINGS BY 2027